+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "T Cell Therapies"

From
From
From
From
From
From
From
Viral Vector Manufacturing Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Viral Vector Manufacturing Market - Forecasts from 2024 to 2029

  • Report
  • August 2024
  • 140 Pages
  • Global
From
Gene Therapy Market Outlook to 2029 - Product Thumbnail Image

Gene Therapy Market Outlook to 2029

  • Report
  • October 2024
  • 83 Pages
  • Global
From
Cell Isolation Market Report and Forecast 2024-2032 - Product Thumbnail Image

Cell Isolation Market Report and Forecast 2024-2032

  • Report
  • August 2024
  • 200 Pages
  • Global
From
From
Innovation Insights: Cell Therapy for Autoimmune diseases - Product Thumbnail Image

Innovation Insights: Cell Therapy for Autoimmune diseases

  • Report
  • January 2025
  • 50 Pages
  • Global
From
Innovation Insights: B-cell Depletion - Product Thumbnail Image

Innovation Insights: B-cell Depletion

  • Report
  • December 2024
  • 55 Pages
  • Global
From
From
Emerging Medical Technologies Spotlight - Product Thumbnail Image

Emerging Medical Technologies Spotlight

  • Newsletter
  • May 2025
  • Global
From
Loading Indicator

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease. T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more